Arcutis Biotherapeutics Inc

NASDAQ:ARQT  
20.61
-1.53 (-6.91%)
Products, Regulatory

Arcutis Announces Positive Topline Results From Stratum Pivotal Phase 3 Trial Of Roflumilast

Published: 06/06/2022 12:00 GMT
Arcutis Biotherapeutics Inc (ARQT) - Arcutis Announces Positive Topline Results From Stratum Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis.
Arcutis Biotherapeutics Inc - Study Met Its Primary Endpoint.
Arcutis Biotherapeutics Inc - Roflumilast Foam Was Well-tolerated With a Favorable Safety and Tolerability Profile.
Arcutis Biotherapeutics Inc - New Drug Application (nda) Submission Anticipated in 1h of 2023.
Arcutis Biotherapeutics Inc - Data Further Support Potential of Roflumilast Foam As a Best-in-class, Once-daily, Non-steroidal Topical Treatment for Seborrheic Dermatitis.
Arcutis Biotherapeutics Inc - More Than 50% of Patients Treated With Roflumilast Foam Achieved an Iga Score of Clear at Week Eight.
Arcutis Biotherapeutics Inc - Roflumilast Foam Also Demonstrated Statistically Significant Improvements Compared to Vehicle on Key Secondary Endpoints.